Picture Berlin Partner Life Sciences Report 2019/2020 Brandenburg 650x80px
Document › Details

R-Biopharm AG. (4/19/16). "Press Release: R-Biopharm AG to Collaborate with HMNC Brain Health on Complementary Diagnostic Test for Optimization of Depression Treatment". Darmstadt.

Organisations Organisation R-Biopharm AG
  Group R-Biopharm (Group)
  Organisation 2 HMNC Value GmbH (HMNC Brain Health)
  Group HMNC (Holsboer / Maschmeyer) (Group)
Products Product companion diagnostic test
  Product 2 antidepressant
Index term Index term HMNC–R-Biopharm: molecular companion diagnostics, 201604– collab €na developm PCR-based ABCB1 CDx for depression therapy
Persons Person Apostel, Frank (R-Biopharm 201311 Director Business Development)
  Person 2 Holsboer, Florian (MPI of Psychiatry + Neuronova Pharmaceuticals AG founder)

R-Biopharm AG announced today it has entered into a collaboration agreement with HMNC Brain Health in the field of complementary diagnostics.

Under this agreement R-Biopharm AG will develop an in vitro PCR (Polymerase Chain Reaction) based genetic test. The goal is to identify ABCB1 gene variants in patients who are treated with antidepressants in order to optimize the efficacy of depression therapy. The collaboration includes the development, regulatory approval, manufacturing and commercialization of the ABCB1 test.

"Complementary diagnostics play a central role in delivering tools that help identifying those individuals who are most likely to benefit from specific treatments" said Dr. Frank Apostel, Vice President Companion Diagnostics, R-Biopharm AG. "We are delighted about this agreement as it expands our service in the field of personalized healthcare. Our goal is to help patients and their physicians to determine the best treatment option available."

"A laboratory test that supports the physician in his treatment decision to choose the best drug and the appropriate dose for the individual patient represents a major improvement in antidepressant treatment." states Professor Florian Holsboer, CEO of HMNC Brain Health. "To develop the ABCB1 test together with R-Biopharm is encouraging and an important step to achieve our ambitious goal even faster."

Complementary diagnostics are increasingly in demand with the recognition that personalized medicine provides a way to improve patient care and reduce health care costs by matching specific therapies to individuals most likely to benefit from them, since all patients do not respond in the same way.

Financial terms of the agreement were not disclosed.


R-Biopharm AG
Companion Diagnostics
Dr. Frank Apostel, Vice President Business Devlopment
An der neuen Bergstraße 17
64297 Darmstadt, Germany

Phone: +49 (0) 61 51 - 81 02-537

About ABCB1:

The ABCB1 gene encodes the P-glycoprotein, which transports various molecules across extra- and intracellular membranes. It functions as transporter for drugs such as antidepressants in the blood-brain barrier. Variants in the ABCB1 gene influence intracerebral concentration of certain antidepressants (e.g., citalopram, paroxetine, amitriptyline, venlafaxine) and thus their efficacy. The ABCB1 test delivers a decision aid for physicians with respect to the type and dosing of antidepressant medication, leading to faster time to remission and higher overall remission rates.

About HMNC Brain Health:

HMNC Brain Health GmbH (Munich, Germany) is specialized in the development of innovative drug treatments for depression, anxiety, and sleep disorders. The portfolio includes laboratory diagnostics that help to stratify patients according to underlying causal mechanisms and to identify the right drug for the right patient. Early stage projects cover the development of molecules that engage with unprecedented targets and work through novel modes of action. Together with partners from academia and with investors, the company utilizes prominent research results to generate innovative and marketable concepts.

About R-Biopharm AG:

R-Biopharm AG (Darmstadt, Germany) is a globally active life science company and a leading provider of reliable test systems for clinical diagnostics and for analyzing human food and animal feedstuffs.

Since 1988, R-Biopharm has been developing innovative products characterized by top quality, reliability and efficiency. A strong sense of responsibility, long-standing experience and a network more than 20 affiliated companies and subsidiaries in Europe, the US, South America, China and Australia, as well as more than 100 distribution partners, make R-Biopharm a prime partner for clients from retail, industry and public institutions looking for answers and solutions for current analytical challenges.

2016-04-19 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at and

Record changed: 2016-04-19


Picture [iito] Männer Ballett 650x80px

More documents for R-Biopharm (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture Kentro Design Corporate and Web Design Berlin 650x65px

» top